LONDON, Sept. 25 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a private biopharmaceutical company focusing on first-in-class, novel non-steroidal anti-inflammatory drugs, today announced it has appointed Dr. Johnson Lau and Dr. David Sidransky to its board of directors.
Dr. Johnson Lau (MBBS, MD, FRCP) brings a wealth of experience from the medical, pharmaceutical and corporate fields, having a distinguished background in both academic medicine and executive-level management of pharmaceutical and biotechnology companies. Dr. Lau previously served Schering-Plough, ICN Pharmaceuticals and its subsidiary Ribapharm, and is currently a senior advisor to Novartis. He was formerly a managing director of healthcare investment banking of Roth Capital Partners. Dr. Lau also serves as a member of the board of directors of Chelsea Therapeutics, VioQuest Pharmaceuticals, XenoBiotic Laboratories and Kinex Pharmaceuticals. Dr. Lau is a Fellow of the Royal College of Physicians of the United Kingdom. He received both his medical degree and doctoral degree from the University of Hong Kong.
Dr. David Sidransky (MD) is the director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine and is also a professor of oncology, otolaryngology-head and neck surgery, cellular and molecular medicine, urology, and genetics and pathology at the university. He is currently vice-chairman of the board of directors of ImClone Systems, lead independent chairman at Alfacell Inc. and serves on the board of directors of Zila Inc. and Xenomics. Dr. Sidransky is a founder of several private biotechnology companies and has served on numerous scientific advisory boards of both private and public companies, including Medimmune, Telik, Roche and Amgen. He was formerly on the board of scientific counselors at the National Institute of Dental and Craniofacial Research and is a member of the Recombinant DNA advisory committee at the National Institutes of Health. Dr. Sidransky sits on numerous editorial boards and has served as senior editor of several cancer-related journals. He is certified in internal medicine and medical oncology by the American Board of Medicine.
"We are excited to have Dr. Lau and Dr. Sidransky join Morria's board," said Mark Cohen, chairman of the board. "Their extensive pharmaceutical and corporate experience will provide valuable guidance in both our clinical development plan with our lead anti-inflammatory compounds and the development of the company from a corporate perspective."
ABOUT MORRIA BIOPHARMACEUTICALS Plc
Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals known as multi- functional anti-inflammatory drugs (MFAIDs). The company's objective is to become a pivotal player in the anti-inflammatory drug market through the introduction of novel drugs for the treatment of a variety of acute and chronic inflammatory conditions including skin, pulmonary and gastro- intestinal inflammatory diseases. For more information please visit http://www.morria.com.
This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order - persons in the business of disseminating information.
SOURCE: Morria Biopharmaceuticals Plc
UK CONTACT: Yuval Cohen, President
53 Davies Street, London, W1K 5JH, United Kingdom
Tel: +44 (0) 207 152 6341 or firstname.lastname@example.org
US CONTACT: Greg Tiberend
Richard Lewis Communications, Inc.
35 West 35 St., Suite 505, New York, NY 10001
Tel: +1 212-827-0020 or email@example.com
|SOURCE Morria Biopharmaceuticals Plc|
Copyright©2007 PR Newswire.
All rights reserved